News - Page 178 - Psychedelic Alpha

Introducing The Psychedelic Practitioner, a new publication by Psychedelic Alpha.

Read more about the article MindMed Announces the Approval of Mescaline Study

MindMed Announces the Approval of Mescaline Study

Post published:May 20, 2021
Post category:Press Release

Read more about the article Dr. Joel Raskin, a leader in psychiatry and neuroscience drug development, joins MINDCURE as Chief Medical Officer

Dr. Joel Raskin, a leader in psychiatry and neuroscience drug development, joins MINDCURE as Chief Medical Officer

Post published:May 20, 2021
Post category:Press Release

Read more about the article Lobe Sciences Secures Production and Supply Agreement for Vitamind Consumer Packaged Goods Products

Lobe Sciences Secures Production and Supply Agreement for Vitamind Consumer Packaged Goods Products

Post published:May 19, 2021
Post category:Press Release

Read more about the article Mydecine Provides Update on Spin-Out of U.S. Cannabis Assets

Mydecine Provides Update on Spin-Out of U.S. Cannabis Assets

Post published:May 19, 2021
Post category:Press Release

Read more about the article MINDCURE Appoints Dr. John Brownstein, the Chief Innovation Officer at Boston Children’s Hospital, as Company Advisor

MINDCURE Appoints Dr. John Brownstein, the Chief Innovation Officer at Boston Children’s Hospital, as Company Advisor

Post published:May 19, 2021
Post category:Press Release

Read more about the article The Chopra Foundation and MindMed Enter Into Letter of Intent to Partner on the Future of Psychedelic Medicines & Mental Wellbeing

The Chopra Foundation and MindMed Enter Into Letter of Intent to Partner on the Future of Psychedelic Medicines & Mental Wellbeing

Post published:May 18, 2021
Post category:Press Release

Read more about the article Entheon Biomedical Announces DMT Drug Supply Agreement with Ofichem Group

Entheon Biomedical Announces DMT Drug Supply Agreement with Ofichem Group

Post published:May 18, 2021
Post category:Press Release

Read more about the article Cybin Granted IRB Approval for Phase II Clinical Trials of its Sublingual Psilocybin Formulation for the Treatment of Major Depressive Disorder

Cybin Granted IRB Approval for Phase II Clinical Trials of its Sublingual Psilocybin Formulation for the Treatment of Major Depressive Disorder

Post published:May 18, 2021
Post category:Press Release

Read more about the article Mydecine Reports First Quarter 2021 Financial Results and Provides Business Update

Mydecine Reports First Quarter 2021 Financial Results and Provides Business Update

Post published:May 18, 2021
Post category:Press Release

Read more about the article More than 80% of Americans report one or more symptoms of depression, and many have turned to substances to cope with negative emotions during COVID-19 Pandemic, according to Field Trip Health’s First Annual “State of Mind” Survey

More than 80% of Americans report one or more symptoms of depression, and many have turned to substances to cope with negative emotions during COVID-19 Pandemic, according to Field Trip Health’s First Annual “State of Mind” Survey

Post published:May 18, 2021
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.